Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

Running, not enrolling

Conditions studied: Eosinophilic Esophagitis

In brief

This study evaluates the decrease in steroid dosing for patients who have achieved remission on a full dose of steroids. Once a patient is in remission they will be enrolled in this study if they choose to decrease the steroid dosing.

Key facts

Study ID

NCT05309590

Run by

Ann & Robert H Lurie Children's Hospital of Chicago

People needed

50

Starts

2014-05-01

Expected to finish

2027-11-01

Last updated by the study team

2026-03-17

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with EoE
• Patients less than 21 years of age at enrollment
• Patients who within the past 12 months have demonstrated histologic remission (<15 eos/hpf as assessed by upper esophagogastroduodenoscopy (EGD) with biopsy ) to the standard induction dose of topical steroids and have remained on this treatment:
• Topical steroid treatment includes only those with previously published results: Swallowed topical fluticasone (i.e. Flovent®), and Swallowed viscous budesonide (i.e. Pulmicort Respules®) mixed with Honey or Splenda®
• Patients who are interested in lowering their dose of topical steroids.

You may not qualify if…

• Patients with EoE who have not demonstrated histologic remission (<15 eos/hpf) to topical steroids.
• Patients who are unable or unwilling to take topical steroids.
• Patients who have changed the vehicle or carrier (e.g. Splenda®or honey ) used to mix with the actual steroid drug, after demonstrating histologic remission.

Where it is running

• Ann & Robert H Lurie Childjren's Hospital of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.